SCHEMBL4286612

SCHEMBL4286612

O=C(NCC1CCCO1)c1cc(-c2cccs2)on1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.71
NPC1 O15118 9/20 0.71
HPGD P15428 8/20 0.71
SMN1; SMN2 Q16637 8/20 0.71
KMT2A Q03164 8/20 0.71
LMNA P02545 5/20 0.71
ALDH1A1 P00352 6/20 0.65
TP53 P04637 3/20 0.65
ATM Q13315 1/20 0.65
MEN1 O00255 6/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2C19 P33261 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
NPSR1 Q6W5P4 2/20 0.58
TSHR P16473 2/20 0.57
POLB P06746 2/20 0.57
MAPT P10636 1/20 0.57
HSD17B10 Q99714 1/20 0.57
PLEC Q15149 1/20 0.55
KDM4E B2RXH2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279011 0.85 RAB9A (0.67) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL16333354 0.83 RAB9A (1.00) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL16334901 0.83 RAB9A (1.00) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL16333352 0.83 RAB9A (1.00) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL9911640 0.81 RAB9A (0.64) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL17788440 0.81 RAB9A (0.60) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL16373566 0.81 NPC1 (0.72) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL17661421 0.79 RAB9A (0.80) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL17661422 0.79 RAB9A (0.80) RAB9ANPC1HPGDSMN1; SMN2KMT2A
SCHEMBL17511025 0.79 RAB9A (0.60) RAB9ANPC1HPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same SIERRA SCIENCES, LLC (US) 2025-09-02 US disclosed
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same SIERRA SCIENCES, LLC 2025-06-05 US disclosed
WO-2023109779-A1 USE OF HETEROCYCLIC COMPOUND IN REDUCING ADVERSE REACTIONS CAUSED BY CHEMOTHERAPEUTIC DRUGS 清华大学 2023-06-22 WO disclosed
US-20140364467-A1 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-12-11 US disclosed
US-8778940-B2 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-07-15 US disclosed
US-20130143885-A1 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-06-06 US disclosed
US-8193225-B2 Isoxazole amides, derivatives and methods of chemical induction of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-06-05 US disclosed
US-8193225-B2 Isoxazole amides, derivatives and methods of chemical induction of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-06-05 US disclosed
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME SIERRA SCIENCES INC. 2009-06-04 US disclosed
US-20090036451-A1 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-02-05 US disclosed
US-20090036451-A1 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same TERT, RNGTT, TERF2 RAB9A 4044/4885NPC1 2894/4885HPGD 1038/4885
US-20140364467-A1 CHEMICAL INDUCERS OF NEUROGENESIS DCX, NES, GAP43 RAB9A 2878/4885NPC1 1941/4885HPGD 289/4885
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same TERT, TELO2, POT1 RAB9A 4662/4885NPC1 4442/4885HPGD 1606/4885
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME TERT, TERF2, RNMT RAB9A 3970/4885NPC1 2996/4885HPGD 649/4885
US-20090036451-A1 Chemical inducers of neurogenesis DCX, NES, GAP43 RAB9A 2878/4885NPC1 1941/4885HPGD 289/4885
US-20130143885-A1 CHEMICAL INDUCERS OF NEUROGENESIS DCX, NES, GAP43 RAB9A 2878/4885NPC1 1941/4885HPGD 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.